Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Brain cancer is one of the most aggressive and difficult-to-treat malignancies. Moreover, in the almost 50 years since the start of the war on cancer, the prospects for people who develop brain cancer have improved much more slowly than those of individuals with other types of cancer. Despite a lack of progress in the clinic, research on this group of conditions is advancing steadily, and treatments with the potential to transform the field are on the horizon.
This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.
This Nature Outlook is editorially independent, produced with financial support from a third party.
About
this content.
Brain cancer comprises only 2% of cancers, but is notoriously difficult to treat. Understanding the location of such tumours, as well as the underlying genetics, will help to tackle this devastating disease.
A flood of sequencing data is enabling researchers to uncover how tumours differ from each other, and what such variation means for treatment strategies.
At Novocure, we are very proud of our ongoing commitment and dedication to improving the lives of people with brain cancer. Our patients, their families and caregivers are at the heart of everything we do. They are the people who drive us forward to achieve our goal of delivering a cancer therapy that can extend and maintain the quality of many patients’ lives. We invited one of our many glioblastoma patients to tell us about his own journey from diagnosis to treatment with TTFields. In his own words, the following inspirational story was provided by Brian Biggs of his own experience of living with this devastating disease.